Evidence map›Paper›PMID 21859247›Full record

Trial reportLeukemia & lymphoma2012

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

Paolo Anderlini, Rima M Saliba, Celina Ledesma, Christina Chancoco, Amin M Alousi, Elizabeth J Shpall, Uday R Popat, Chitra M Hosing, Issa F Khouri, Yago Nieto and 6 more

Registry-linked trialAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03339700 (Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03339700 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia

TypeinterventionalSponsorInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranRan2018 to 2021Enrolled15ConditionsAcute Lymphoblastic Leukemia, AdultArmsGemcitabine, Busulfan, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Paolo Anderlini
Rima M Saliba
Celina Ledesma
Christina Chancoco
Amin M Alousi
Elizabeth J Shpall
Uday R Popat
Chitra M Hosing
Issa F Khouri
Yago Nieto
Stefan Ciurea
Anas Younes
Michelle A Fanale
Sandra Acholonu
Rosamar Valverde
Richard E Champlin

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Salvage TherapyStem Cell TransplantationAdultAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDeoxycytidineFemaleGemcitabineHodgkin DiseaseHumansKaplan-Meier EstimateMaleMelphalanMiddle AgedRecurrenceRemission InductionDeoxycytidinefludarabineGemcitabineMelphalanVidarabine

Identifiers

PMID21859247
PMCPMC4245073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.